Retatrutide experiences: trial findings, anecdotes and adverse events
A personal post is not a clinical trial, and a trial result is not a promise about an individual. Published Phase 2 research measured specified outcomes in selected participants under controlled conditions; qualitative interviews describe participants in a study, not a representative sample of everyone. We found no directly verifiable individual public retatrutide accounts suitable to reproduce here, so no testimonial is quoted or implied.
Published: · Last reviewed:
Evidence summary, not medical advice. Retatrutide is investigational. Any research product is not a medicine and is not for human use.
Related research reading
What controlled studies actually measured
The Phase 2 obesity trial randomly assigned 338 adults to retatrutide or placebo and followed them for 48 weeks; body-weight change was the primary endpoint at week 24. A separate Phase 2 diabetes study compared assigned doses with placebo and dulaglutide. These trial populations, protocols and endpoints—not anecdotes—define what the publications report.
Public anecdotes are not verified evidence
Social posts and forum summaries often lack a verifiable identity, product provenance, dose, co-interventions, follow-up or independent confirmation. This page uses no verified individual public accounts and does not describe any experience as typical or frequent. A 2025 qualitative paper analyses interviews with Phase 2 trial participants; it is valuable research about reported perceptions, but it is not an independent collection of public testimonials.
Negative events and limits matter too
In Phase 2, gastrointestinal events such as nausea, diarrhoea and vomiting were among the reported adverse events; trial rates and tolerability depend on study conditions and do not determine any individual outcome. Sponsor-reported Phase 3 topline updates are not a substitute for full peer-reviewed reports. Do not use online accounts to judge safety or to self-treat.
Research references
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial — New England Journal of Medicine / PubMed, PMID 37366315; DOI 10.1056/NEJMoa2301972
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes — The Lancet / PubMed, PMID 37385280; DOI 10.1016/S0140-6736(23)01053-X
- Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial — Obesity Pillars / ScienceDirect, 2025;16:100220; DOI 10.1016/j.obpill.2025.100220
- TRIUMPH-1: A Study of Retatrutide in Participants Who Have Obesity or Overweight — ClinicalTrials.gov, NCT05929066
Reference questions
Are the stories online verified retatrutide user experiences?
Not by this review. We found no individual public account with enough directly verifiable context to responsibly reproduce it. Anonymous claims cannot confirm the substance, exposure, health context or outcome.
Does this page give advice about taking retatrutide?
No. It is an evidence-literacy summary, not medical advice. Retatrutide remains investigational; any product sold as a research material is not a medicine and is not for human use.